Induced pluripotent stem cells as custom therapeutics for retinal repair: Progress and rationale  by Wright, Lynda S. et al.
lable at ScienceDirect
Experimental Eye Research 123 (2014) 161e172Contents lists avaiExperimental Eye Research
journal homepage: www.elsevier .com/locate/yexerInduced pluripotent stem cells as custom therapeutics for retinal
repair: Progress and rationaleq
Lynda S. Wright a,b, M. Joseph Phillips a,b, Isabel Pinilla c, Derek Hei a, David M. Gamma,b,d,*
aWaisman Center, University of Wisconsin, Madison, WI, USA
bMcPherson Eye Research Institute, University of Wisconsin, Madison, WI, USA
cDepartment of Ophthalmology, Lozano Blesa Hospital and Aragones Health Sciences Institute, Zaragoza, Spain
dDepartment of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI, USAa r t i c l e i n f o
Article history:
Received 3 September 2013
Accepted in revised form 2 December 2013
Available online 16 February 2014
Keywords:
human induced pluripotent stem cells




clinical good manufacturing practice
transplantationAbbreviations: AMD, Age-related macular degene
Regulations; cGMP, clinical goodmanufacturing practi
embryonic stem cells; FDA, Food and Drug Administr
onic stem cells; iPSCs, induced pluripotent stem ce
pluripotent stem cells; HLA, human leukocyte antige
ence on Harmonization; LAL, Limulus amoebocyte a
NR, neural retina; PTC, points to consider; QC, qual
mented epithelium; RP, retinitis pigmentosa.
q This is an open access article under the CC
creativecommons.org/licenses/by-nc-nd/3.0/).
* Corresponding author. University of Wisconsin,
Highland Avenue, Madison, WI 53705, USA. Tel.: þ1 6
3479.
E-mail address: dgamm@wisc.edu (D.M. Gamm).
0014-4835/$ e see front matter  2013 The Authors.
http://dx.doi.org/10.1016/j.exer.2013.12.001a b s t r a c t
Human pluripotent stem cells have made a remarkable impact on science, technology and medicine by
providing a potentially unlimited source of human cells for basic research and clinical applications. In
recent years, knowledge gained from the study of human embryonic stem cells and mammalian somatic
cell reprogramming has led to the routine production of human induced pluripotent stem cells (hiPSCs)
in laboratories worldwide. hiPSCs show promise for use in transplantation, high throughput drug
screening, “disease-in-a-dish” modeling, disease gene discovery, and gene therapy testing. This review
will focus on the ﬁrst application, beginning with a discussion of methods for producing retinal lineage
cells that are lost in inherited and acquired forms of retinal degenerative disease. The selection of
appropriate hiPSC-derived donor cell type(s) for transplantation will be discussed, as will the caveats and
prerequisite steps to formulating a clinical Good Manufacturing Practice (cGMP) product for clinical
trials.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Efforts to provide personalized cell-based treatments for
degenerative diseases were greatly aided by the advent of somatic
cell reprogramming technology, which holds potential to generate
patient-speciﬁc cells of any type for research and clinical purposes.
The retina is well-suited to be the ﬁrst site for this therapeutic
application, as all of the major retinal cell types, including photo-
receptors and retinal pigmented epithelium (RPE), have been suc-
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Published by Elsevier Ltd. All righ(hiPSCs). In addition, insights into the donor cell types and differ-
entiation stages needed to treat particular retinal diseases are
available from transplantation studies using embryonic stem cells
(ESCs) and primary retinal tissues, as well as iPSCs. As a result,
strategies have been developed to usher hiPSCs into clinical trials
for retinal disease, at least one of which will be realized in the near
future using autologous donor cell sources. The capability for gene
repair in hiPSCs further enhances their potential to be employed in
autologous cell transplantation. However, challenges and concerns
remain regarding transplantation of at least some hiPSC-derived
retinal cell types. In particular, inherent difﬁculties in achieving
clinical-grade status for hiPSC-derived photoreceptors will need to
be addressed before these critical cell types can be used to treat
outer retinal degenerative diseases such as age-related macular
degeneration (AMD) and retinitis pimentosa (RP).2. Background
Loss of vision exacts a tremendous societal burden in terms of
quality of life, decrease in productivity and health care expenditure.
Retinal degenerative diseases such as AMD and RP contribute to a
large proportion of such costs, with the certainty of a dramatic
increase in the prevalence of AMD given the growing population ofts reserved.
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gies for retinal cell survival, repair and replacement for these and
other retinal disorders.
The relative simplicity of the retina compared to other regions
of the central nervous system, its surgical accessibility, and the
existence of sophisticated, noninvasive anatomical and functional
assessment tools make the retina particularly amenable to the
application of novel, cutting edge treatment modalities. To date,
these inherent properties have been exploited for the develop-
ment and delivery of gene- and drug-based therapeutics. For
example, gene therapy has been used in clinical trials to treat one
form of Leber congenital amaurosis (Jacobson et al., 2012;
Maguire et al., 2009), while pharmacological agents have been
introduced via intraocular injection or encapsulated cell tech-
nology in an attempt to mitigate diseases such as wet AMD and
RP (Birch et al., 2013; Haller, 2013; Kauper et al., 2012). However,
for these types of treatments to succeed, retinal cell types (e.g.,
photoreceptors and RPE) and structural connections must still
exist in vivo.
In disease states where there is signiﬁcant destruction of retinal
architecture and/or cell loss, a cell bypass or replacement approach
is required. The prospect of cell bypass has been explored using
epiretinal prostheses (such as the FDA-approved Argus II) or sub-
retinal micro-photodiode arrays, which have succeeded in
restoring some visual function to blind individuals (da Cruz et al.,
2013; Zrenner et al., 2011). While such results constitute a major
accomplishment, retinal prosthetics and other potential photore-
ceptor bypass methods, including optogenetics, may not be the
optimal ormost convenient choice formany patients suffering from
vision loss. A potential alternative is the use of cell-based therapy to
replace host cells within the neural retina (NR) and/or RPE, pro-
vided a suitable supply of donor cells can be identiﬁed. Human
prenatal retinal tissue was one of the ﬁrst donor sources to be
examined in patients. In one report, subretinal injection of a sus-
pension of prenatal NR cells in RP patients resulted in a transient
improvement in visual acuity (Humayun et al., 2000). Improve-
ments in visual acuity were also documented in a subset of AMD
and RP patients who underwent submacular transplantation of
sheets of prenatal NR with attached RPE (Radtke et al., 2008).
However, the use of human fetal tissue is problematic due to ethical
issues surrounding its procurement, as well as limitations in the
amount of donor material that can be obtained (Gamm et al.,
2008b; Kelley et al., 1995).
Human pluripotent stem cells provide another potential
donor source for retinal cell transplantation. Embryonic stem
cells (ESCs) are obtained from the inner cell mass of the blas-
tocyst and can be maintained and expanded indeﬁnitely in cul-
ture as undifferentiated cells. When prompted to differentiate,
ESCs have the theoretical capacity to produce any cell type, with
the caveat that the cell-speciﬁc developmental program can be
adequately recapitulated in vitro. In particular, cells of a retinal
lineage have been derived from mouse, nonhuman primate and
human ESCs (hESCs) (Ikeda et al., 2005; Lamba et al., 2006;
Meyer et al., 2009; Osakada et al., 2008), and are the subject
of a separate review in this issue (Reynolds and Lamba). In
contrast to ESCs, induced pluripotent stem cells (iPSCs) can be
derived from somatic cells of adult individuals, and therefore
constitute a unique, powerful and patient-speciﬁc tool for
modeling disease and developing cell-based treatments for
retinal degenerative diseases. The present review will focus on
the latter indication, with special attention given to data accu-
mulated thus far with human iPSCs (hiPSCs). In addition, the
challenge of generating clinical grade cells from hiPSCs and the
indications for using them for retinal cell replacement will be
examined.3. Generation of RPE and neural retinal cell types from iPSCs
3.1. Production of iPSCs
Landmark studies describing the reprogramming of vertebrate
somatic cells began more than 50 years ago (Gurdon, 1962) and
culminated in the discovery of the essential transcription factors
that were necessary and sufﬁcient to convert a somatic cell to a
state highly similar to that of a pluripotent embryonic stem cell in
mice (Takahashi and Yamanaka, 2006). Shortly afterward, both the
Yamanaka and Thomson laboratories succeeded in using inte-
grating retroviruses to deliver a combination of either OCT4, SOX2,
KLF4 and cMYC (Takahashi et al., 2007) or OCT4, SOX2, NANOG and
LIN28 (Yu et al., 2007) to reprogram human ﬁbroblasts to a
pluripotent state with the requisite capacity to yield progeny
indicative of the three germ layers. Since those initial reports, the
production of normal and disease-speciﬁc hiPSC lines has escalated
rapidly [for review, see Egashira et al., 2013; Grskovic et al., 2011].
The ability to recapitulate a pathological phenotype with hiPSCs
in vitro is particularly noteworthy, as it has important applications
for disease modeling and drug discovery.
A more ambitious goal is to generate pluripotent lines from an
individual patient, repair any underlying genetic defect(s) ex vivo,
and then transplant appropriate differentiated cell type(s) in an
effort to advance autologous cell replacement therapies. Paramount
in each of these applications of iPSC technology is the ability to
target their differentiation toward cell types of interest. A potential
concern is the ﬁnding that iPSCs can exhibit varying degrees of
epigenetic, transcriptional and genomic changes when compared
to hESCs [for review see Bilic and Izpisua Belmonte, 2012]. These
differences appear to be of a stochastic nature and may stem from
low programming efﬁciency, culture conditions and/or epigenetic
memory, among other possible causes. As these questions
regarding reprogramming technology continue to be investigated
and satisfactorily addressed, it is likely that hiPSCs will be
increasingly employed in patient therapies.
3.2. Production of RPE from hiPSCs
Following the successful generation of retinal cells from mouse
and human ESCs, researchers applied analogous differentiation
protocols to iPSCs derived from ﬁbroblasts, RPE, and T lymphocytes,
and succeeded in converting them to retinal cells as well (Buchholz
et al., 2009, 2013; Carr et al., 2009; Hirami et al., 2009; Meyer et al.,
2009; Phillips et al., 2012). A variety of methods have been used to
generate RPE from iPSCs, most of which are based on ESC protocols
[for review, see (Rowland et al., 2012)]. Most commonly, patches of
RPE are allowed to spontaneously differentiate after withdrawal of
mitogens from adherent cultures of pluripotent stem cells. RPE
patches produced in this manner are subsequently isolated by
manual dissection. Mixed pluripotent stem cell cultures can also be
treatedwith exogenous factors to accelerate the production of large
populations of RPE. When dissociated en masse and re-plated, these
highly proliferative monolayers of RPE show a tendency to
outcompete contaminating cells over a series of passages (Buchholz
et al., 2013).
A second method for RPE generation involves the formation of
“embryoid bodies” (EBs) from hiPSCs as a ﬁrst step in the neuro-
ectodermal differentiation process, followed by plating of the sus-
pended EBs to a coated surface. Thereafter, adherent pigmented
RPE patches appear over time and are dissected away from un-
wanted cell types. Lastly, ESC- and iPSC-derived RPE can be grown
in aggregate suspension as pigmented spheroids, similar to RPE
spheroid cultures derived from human donor retinal tissue (Gamm
et al., 2008a; Meyer et al., 2009). Once plated, these pigmented
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expanded (Gamm et al., 2008a).
Regardless of the method used to derive them, there are com-
mon criteria for evaluating stem cell-derived RPE populations,
which include 1) formation of characteristic hexagonal cell
morphology, 2) appearance of pigmentation, 3) establishment of
apical/basal polarity, and 4) evidence of RPE functions such as
phagocytosis of photoreceptor outer segments, tight junction for-
mation, growth factor secretion, and/or vectorial ﬂuid ﬂow, among
others [for review, see Bharti et al., 2011]. In addition, iPSC-derived
RPE should express signature genes and proteins consistent with
bona ﬁde prenatal and adult human RPE (Strunnikova et al., 2010),
such as those involved in melanogenesis and retinoid recycling.
Using the embryoid body method, Singh et al. derived hiPSC-
RPE from two patients bearing distinct mutations in BEST1, the
gene responsible for Best vitelliform macular dystrophy (BVMD)
(Singh et al., 2013b). When compared to RPE cultured from human
prenatal eye, hiPSC-RPE from the BVMD patients and their unaf-
fected siblings displayed identical cellular morphology, capacity for
pigmentation and tight junction formation, and RPE gene and
protein expression. Disease-speciﬁc functional differences were
also demonstrated, with mutant hiPSC-RPE showing increased
accumulation of autoﬂuorescent material following chronic rod
outer segment feeding, as well as altered ﬂuid ﬂux and delayed
RHODOPSIN degradation when compared to control hiPSC-RPE
cultures. These ﬁndings demonstrate the ability of iPSC-derived
RPE to approximate established morphological and functional
standards and model disease phenotypes.
3.3. Neural retina differentiation from hiPSCs
In contrast to protocols aimed at generating RPE, methods for
the production of human neural retinal (NR) cell types from
pluripotent stem cells tend to require greater manipulation of the
culture environment (Hirami et al., 2009; Lamba et al., 2010;
Mellough et al., 2012; Meyer et al., 2011). Techniques differ in
their reliance on endogenous vs. exogenous factors tomodulate key
signaling pathways (e.g., Wnt, BMP and Nodal), with the purpose of
guiding iPSCs in a stepwise fashion towards a retinal fate (Rowland
et al., 2012; Meyer et al., 2011). Both adherent and 3-D aggregate
methods of retinal differentiation (and combinations thereof) have
been employed, each possessing distinct advantages and disad-
vantages with regard to complexity and expense, scalability,
adaptability and capacity to yield speciﬁc retinal cell types. How-
ever, most culture systems support an orderly, highly conserved
sequence of events that approximates normal retinal development.
In a seminal report published in 2011, the Sasai laboratory
generated self-organizing 3-D structures from mouse ESC aggre-
gates that mimicked in vivo optic cups to a remarkable degree
(Eiraku et al., 2011). These structures displayed interkinetic nuclear
migration, self-patterning into NR and RPE domains, and retinal
stratiﬁcation. 3-D optic vesicle-like structures (OVs) have also been
reported using human iPSCs (Meyer et al., 2009; Phillips et al.,
2012) and ESCs (Boucherie et al., 2013; Meyer et al., 2011, 2009;
Nakano et al., 2012). Building on an earlier study (Meyer et al.,
2009), Meyer et al. (2011) showed in 2011 that human iPSCs and
ESCs could generate neuroepithelial-like clusters of retinal pro-
genitorswith numerous characteristics of developing optic vesicles.
Based on their distinct light microscopic appearances, these human
pluripotent stem cell-derived OVs could be manually separated
from coexistent populations of early forebrain neurospheres and
cultured in isolation. Upon further differentiation, hiPSC- and hESC-
OVs produced all major NR cell types in a time frame and sequence
that resembled retinal development in vivo. Furthermore,
RECOVERINþ cells demonstrated a characteristic photoreceptorelectrophysiological response after stimulation with membrane-
permeable 8-Br-cGMP (Meyer et al., 2011). The potential for hu-
man pluripotent stem cells to produce OV structures was also
shown by the Sasai laboratory in 2012 following adaptation of their
mouse ESC optic cup protocol to yield OV structures from hESCs
(Nakano et al., 2012). The 3-D hESC-OVs thus produced displayed a
precise apical-basal orientation with retinal progenitors located in
a region approximating the prenatal neuroblastic layer. Subse-
quently, retinal cell types appeared in a sequential fashion that self-
stratiﬁed into organized tissues similar to the developing human
retina.
Like OVs derived from hESCs, hiPSC-OVs have also been shown
to self-assemble into rudimentary, multi-layered retinal tissues
(Phillips et al., 2012). The hiPSC-derived tissue-like structures
initially possessed a neuroblastic layer comprised of proliferating
VSX2þ cells (Fig. 1A), which gives rise to an inner layer of BRN3þ/
HUc/dþ/TUJ1þ ganglion cells (Fig. 1B and C), an intermediate layer
of retinal interneurons (e.g., CALRETININþ/BRN3þ amacrine cells
and post-mitotic VSX2þ bipolar cells), and an outer layer of
RECOVERINþ photoreceptor-like cells (Fig. 1D and E) that express
synaptophysin (Fig. 1F). RECOVERINþ cells begin to predominate in
hiPSC-OV cultures by day 90, although by this time the laminar
structure of the OVs can become less organized (Fig. 2A). Gentle
dissociation of hiPSC-OVs at this stage of differentiation facilitates
the preparation of large numbers of hiPSC-derived photoreceptors
(Fig. 2B) and other neuroretinal cell types for further study and/or
transplantation. Glia, on the other hand, are infrequently found in
hiPSC-OVs at this time point (Fig. 2C). Consistent with their early
birth during retinogenesis, cones are the earliest photoreceptor cell
type produced in these cultures, whereas rods were much less
prevalent until later differentiation time points. In contrast, rods
are abundant in mouse pluripotent stem cell cultures, likely due to
the shorter maturation time needed for mouse vs. human retina
(Eiraku et al., 2011).
With regard to neuronal connectivity in differentiating hiPSC-
OVs, the appearance and appropriate co-expression of pre- and
post-synaptic markers such as VGLUT-1, GLUR2, SNAP-25, MGLUR6
and SYNAPSIN-1 has indicated the potential for the formation of
synapses (Fig. 1F) (Phillips et al., 2012). Thus, hiPSCs can serve not
only as a source of individual NR cell types for transplantation, but
perhaps also for retinal structures capable of more complex tissue
reconstruction.
4. iPSC-based retinal transplantation strategies
4.1. Cell transplantation for the inner retina
The aforementioned studies verify that iPSCs can be differenti-
ated into cells that are indisputably retinal and theoretically could
be used as a source for transplantation. However, many challenges
lie ahead in the quest to optimize hiPSC-based therapeutic strate-
gies. These issues include the choice, characterization and prepa-
ration of the donor cell population and selection of disease
model(s) for preclinical testing. Retinal ganglion cells (RGCs) are the
ﬁrst differentiated neuronal cell type to be detected in both hESC
and hiPSC-derived retinal cultures, mirroring the cell birth order of
normal mammalian retinogenesis. They are also the major cell type
affected in glaucoma and other optic nerve pathologies; thus, there
is considerable interest in developing methods to replace or
regenerate RGCs in vivo (Johnson et al., 2011). To accomplish the
lofty goal of complete RGC replacement, donor cells must extend
processes out of the retina along the optic nerve and into the visual
centers of the brain, where they would need to synapse with reti-
notopically arranged resident neurons. Although the degree of
plasticity within these centers is probably underestimated, it
Fig. 1. Optic vesicle-like structures (OVs) derived from human induced pluripotent stem cells (hiPSCs) can form layered retinal structures containing photoreceptor-like cells with
potential to form synapses. (A) After 20 days of differentiation, proliferating Ki67þ/VSX2þ retinal progenitor cells derived from hiPSCs form a structure resembling the optic vesicle
in vivo. (B) An inner layer consisting of post-mitotic HuC/Dþ neurons and an outer neuroblastic layer of Ki67þ/VSX2þ retinal progenitors can be detected by 50 days. (C) A similar
pattern is observed at day 50 with the retinal ganglion cell marker BRN3 and the retinal progenitor marker SOX2. (D) RECOVERIN þ cells with the morphology of immature
photoreceptors are located in the outermost layer of the OV where they (E) send processes towards the inner neuronal layers of hiPSC-OVs by day 70. (F) Synaptic proteins such as
SYNAPTOPHYSIN are expressed in RECOVERIN þ cells by 90 days, indicating the potential for synapse formation. Scale bar ¼ 50 mm (panels A, B and C); 20 mm (panel D); 10 mm
(panel E); 5 mm (panel F).
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brain to make sense of information coming from donor RGCs. For
these and other reasons, RGC replacement likely faces the most
formidable hurdles of any donor retinal cell type. Alternative ap-
proaches aimed at axonal regeneration instead of whole cell
replacement may be more fruitful, but such strategies require the
viable presence of at least the cell bodies of host RGCs. Interestingly,
it was recently shown that hematopoetic stem cells or mESCs can
undergo fusionwith damaged host ganglion and amacrine cells and
transiently reprogram them to a proliferative precursor/pluripotent
state (Sanges et al., 2013). These reprogrammed cells proved
capable of differentiating into neurons with the phenotype of the
original retinal cells, extending projections to the optic nerve, and
partially restoring light-evoked responses.
4.2. RPE transplantation
Compared to diseases that cause RGC loss, degenerative diseases
of the outer retina (i.e., RPE and/or photoreceptors) pose fewer
challenges to cell replacement therapies, due in part to the highly
localized, short-range intercellular connections they require. In
particular, the outward simplicity of the RPE, with its monolayer
structure and relative cell homogeneity, has made it an appealing
target for repair strategies. Furthermore, the RPE layer is situated
adjacent to the vestigial embryonic retinal ventricular space, and
the relative ease of generating a transient retinal detachment at this
site has been routinely exploited in the subretinal delivery of donor
graft materials and other therapeutics. The RPE carries out a
number of complex functions that are critical for maintenance of
photoreceptor health and activity (Strauss, 2005) and, as
mentioned previously, many of these functions have been reca-
pitulated in vitro by RPE derived from hESCs and hiPSCs (Kokkinakiet al., 2011; Meyer et al., 2011; Osakada et al., 2009; Singh et al.,
2013b).
The capacity to generate substantial amounts of highly enriched,
functional RPE from pluripotent stem cells has made this cell type a
prime candidate for transplantation; however, there is limited data
on the efﬁcacy of hiPSC-RPE in animal models of retinal disease.
One model system that has been used to test hiPSC-RPE is the Royal
College of Surgeons (RCS) rat. The dystrophic RCS rat has amutation
in a gene crucial for photoreceptor outer segment phagocytosis
(Mertk), which results in primary loss of RPE and secondary
photoreceptor degradation. Similar to studies using hESC-RPE and
other retinal and non-retinal cell types (Gamm et al., 2007; Idelson
et al., 2009; Lund et al., 2006; McGill et al., 2007;Wang et al., 2008),
injection of dissociated hiPSC-RPE into the subretinal space of RCS
rats resulted in long-term photoreceptor survival and retention of
visual function (Carr et al., 2009). Similarly, Li et al. treated 2 day
postnatal SCID Rpe65rd12/Rpe65rd12 mice with a subretinal bolus of
hiPSC-RPE and showed that donor cells integrated into the host
RPE. ERG recordings revealed that the b-wave response was
maintained in the treated eye compared to the untreated fellow eye
(Li et al., 2012). Furthermore, no evidence of tumor formation was
seen up to 6 months following transplantation.
Although the RCS rat and other rodent models of RPE degen-
eration have value for testing RPE replacement strategies, the
similarity in therapeutic response observed from a wide array of
subretinal manipulations may in part stem from a general neuro-
protective mechanism. Nevertheless, efﬁcacy studies in RCS rats
have been sufﬁcient to support the initiation of clinical trials for
atrophic AMD and Stargardt macular dystrophy using subretinal
injections of dissociated hESC-RPE. In addition, a trial using hiPSC-
RPE to treat exudative AMD has been announced (Cyranoski, 2013).
Of note, the hiPSC-RPE trial utilizes monolayer sheets of cells,
Fig. 2. (A) A large number of RECOVERINþ cells is present in bulk cultures of plated day 90 hiPSC-OVs, as seen in this en face image. (B) Upon dissociation of day 90 hiPSC-OV
cultures, an enriched population of CRXþ/RECOVERINþ photoreceptor-like cells can be obtained (a 40 magniﬁed image of the photoreceptor-like cells is shown in the inset).
(C) Compared to the number of RECOVERINþ cells, relatively few GFAPþ glia are found in dissociated day 90 hiPSC-OVs. Scale bar ¼ 100 mm.
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implantation. This detail is potentially critical, since cell polariza-
tion and tight junction formation are necessary for many RPE
functions (Diniz et al., 2013). Looking to the future, prefabricated
RPE monolayers could also serve as a platform for combined
transplantation of photoreceptors and RPE, which will likely be
necessary to treat diseases where both of these cell types are lost
(Hynes and Lavik, 2010; Rowland et al., 2013).
4.3. Photoreceptor transplantation
While replacement of RPE alone may be beneﬁcial for certain
disease indications, a source of photoreceptors will be needed to
treat retinal degenerative diseases where there is extensive
photoreceptor degeneration (e.g., most RP and RP-like disorders)
with or without RPE involvement. In one of the few transplantation
studies published to date using retinal hiPSCs, human photore-
ceptors expressing GFP under the control of the interphotoreceptor
retinoid binding protein (IRBP) receptor were isolated by FACS and
injected into the subretinal space of wildtype mice (Lamba et al.,
2006, 2010). A limited number of donor photoreceptors migrated
into the outer nuclear layer (ONL) after subretinal injection, similar
to FAC-sorted, hESC-derived photoreceptors. Using a similar strat-
egy, photoreceptors derived from porcine iPSCs were labeled with a
lentiviral construct (retinol-binding protein 3 (RBP3)-GFP) and
detected at a 1% frequency in the ONL following chemical-induced
host retinal damage (Zhou et al., 2011). As opposed to subretinalinjection, intravitreal introduction of iPSCs appeared less effective
at promoting outer retinal integration (Parameswaran et al., 2010).
Even less data is available regarding the effect of iPSC-derived
donor retinal cells on host retinal function. However, in a study
that employed the Rho/ mouse model, a dose-dependent
improvement in ERG responses was seen following subretinal
transplantation of allogeneic iPSC-derived retinal donor cells
(Tucker et al., 2011).
Although work is ongoing to optimize hiPSC-photoreceptor
survival, integration and function post-transplantation, prior
studies using other photoreceptor cell sources offer considerable
guidance in this regard. As ﬁrst shown by MacLaren et al. (2006),
postmitotic rod precursors isolated from early postnatal Nrl-GFP
mice differentiated into mature rods and established synaptic
connectivity inwildtype mice. This same donor rod population also
restored light responses in Rho/ mutant mice (MacLaren et al.,
2006). Since that initial report, rod precursor cells isolated from
both developing mouse retina and mouse ESCs have been trans-
planted into many mouse models (Barber et al., 2013; Gonzalez-
Cordero et al., 2013; Homma et al., 2013; Singh et al., 2013a). In
the case of the Gnat1/ model of congenital stationary night
blindness, scotopic visionwas restored when P4eP8 rod precursors
were injected into the subretinal space (Pearson et al., 2012). Donor
photoreceptors from more mature mice have also been shown to
integrate into host retina, albeit at a lower efﬁciency (Gust and Reh,
2011). In the aforementioned studies, reporter line transgenic ani-
mals were used to identify and isolate the desired donor cell
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applications. At present, no human photoreceptor-speciﬁc cell
surface markers suitable for FACS have been described, but a
combination of CD73 and CD24 has been used to enrich for
photoreceptor precursors from stage-speciﬁc mouse embryonic
retina (Lakowski et al., 2011).
Producing a population of donor photoreceptors from a human
source is one of many necessary steps in the development of an
effective strategy for outer retinal repair. Understanding and
manipulating the host retinal environment, which varies substan-
tially based on the type and stage of disease, are critical tasks as
well. The integrity of the outer limiting membrane (OLM), the
presence and extent of glial scarring, and the status of the inner
retinal circuitry, among other factors, have a profound inﬂuence on
donor cell survival and integration (Barber et al., 2013). Although
the use of aminoadipic acid or ZO-1 siRNA to disrupt the mouse
retina OLM can signiﬁcantly increase the number of integrated
photoreceptors, untoward effects of such treatment, including glial
activation and dissolution of RPE tight junctions, preclude their use
in human patients (Pearson et al., 2010; West et al., 2008). Fortu-
nately, not all retinal diseases appear to possess complex barriers to
integration. Without pretreatment, late-stage rd1 mouse retina
transplanted with mouse rod precursors formed an anatomically
distinct donor cell stratum that matured into a putative outer nu-
clear layer, with concurrent restoration of light-activated pupillary
responses and light-mediated behavior (Singh et al., 2013a).
The integrity of the host retinamay also be important in the host
immune response to donor cells. The subretinal space has been
shown to be an immune privileged site in the healthy eye. However,
when ocular integrity is compromised by RPE loss and/or degra-
dation of the blood-retinal barrier, macrophage invasion and
microglial and T-lymphocyte activation can initiate an immune
response, resulting in graft rejection (Streilein et al., 2002). Even
when postnatal photoreceptor donor cells share partial MHC
haplotype identity with the host, a chronic immune response can
attenuate long-term graft survival in the absence of immune sup-
pression (West et al., 2010). Taken together, these ﬁndings under-
score the key role of the disease-speciﬁc milieu in donor cell
survival and integration, and imply that an unmatched or partially
matched allogenic hiPSCebased treatment scheme may not be
adequate for all degenerative diseases. In contrast, the use of
autologous hiPSC cell types carries a high likelihood of circum-
venting immune complications.
5. The potential for iPSCs to be used for autologous tissue
repair
The ability to derive customized hiPSC lines has opened the door
to new frontiers in personalized medicine. In a landmark study,
homologous recombination was used to repair a single copy of the
bs globin gene in iPSCs derived from a humanized sickle cell mouse.
When autologous transplantation was performed using hemato-
poietic cells bearing the corrected sickle cell allele, the anemia
phenotype was corrected (Hanna et al., 2007). Since that publica-
tion, gene correction has been performed in hiPSCs for several
monogenetic blood disorders and tested in vitro and in xenografts
(Simara et al., 2013).
Gene correction in hiPSCs has also been used to repair a muta-
tion responsible for gyrate atrophy (GA), a progressive blinding
disease that primarily affects RPE, leading to secondary photore-
ceptor loss. By employing bacterial artiﬁcial chromosome-
mediated homologous recombination, an A226V mutation in
ornithine aminotransferase (OAT) was corrected in hiPSCs derived
from a GA patient (Howden et al., 2011). RPE differentiated from the
uncorrected GA hiPSCs showed very low levels of OAT enzymaticactivity, whereas RPE from gene-corrected hiPSCs had OAT activity
comparable to human prenatal RPE and RPE differentiated from
hESC and control hiPSC lines (Meyer et al., 2011). In addition, it was
shown that the process of OAT gene repair did not add to the
mutational load, nor did it increase genetic instability (Howden
et al., 2011). However, the cost and effort that would be required
to produce and test clinical grade, gene-corrected cells makes this
option unwieldy with currently available technology. With this in
mind, in cases where the consequences of genetic defects or risk
factors are not manifested for many years, gene repair may not be
necessary for autologous transplantation. An important example is
AMD, where multiple genetic risk factors are known to increase
patients’ susceptibility to RPE dysfunction and death, but only after
many decades. In this scenario, genetic manipulation of donor
hiPSCs would not be required, assuming an adequate restoration of
cellular “youth” occurs through the reprogramming process. In
keeping with this thought process, the ﬁrst clinical trials using
autologous, uncorrected hiPSC-RPE will target AMD.
Regardless of whether gene repair is necessary, other potential
safety concerns remain for hiPSC transplantation. For example,
tumor formation could result if residual undifferentiated cells are
present within the donor cell population. While progress has been
made in the development of methods to detect and remove re-
sidual pluripotent cells (Kobayashi et al., 2012; Kuroda et al., 2012;
Tsuji et al., 2010; Tucker et al., 2011), further advances in this area
are anticipated.
Another prerequisite for the use of hiPSCs in retinal disease is
the evaluation of immunogenicity of donor retinal progeny in an-
imal models. Zhao et al. reported that the transplantation of un-
differentiated ESCs and iPSCs into syngenic mice incited an
immune response resulting in regression of teratoma growth (Zhao
et al., 2011). Although the issues raised in that report deserve
serious consideration, investigations into immune rejection would
optimally be performed using the speciﬁc differentiated cell pop-
ulations needed for tissue repair. In a separate report, ten iPSC and
ﬁve ESC lines derived from C57BL/6 were injected into syngeneic
recipients, whereupon negligible teratoma regression and immune
responses were found (Araki et al., 2013). Furthermore, no unto-
ward effects were detected when neurospheres derived from
allogenic murine iPSCs were transplanted into a spinal cord injury
model (Tsuji et al., 2010).
Xenograft studies are inherently insufﬁcient to fully examine
the issues surrounding the clinical use of human iPSCs, leading
some groups to generate iPSCs from nonhuman primate species to
test in autograft experiments [for review, see Wu et al., 2012]. To
date, several cell types have been derived from nonhuman primate
iPSCs, including RPE (Okamoto and Takahashi, 2011), but there have
been only a few publications describing the use of these cells in
transplantation experiments. Recently, iPSCs derived from
nonhuman primates were partially differentiated toward a dopa-
minergic neuronal fate and transplanted into an autologous hem-
iparkinsonian model (Emborg et al., 2013). After six months,
mature neurons and glial cells arose from the transplanted pro-
genitor populationwith little evidence of microglia, macrophage or
lymphocyte inﬁltration. Although no functional assays were per-
formed, this study in a nonhuman primate model provides support
for autologous hiPSC transplantation in humans.
6. The path to hiPSC clinical trials: manufacturing clinical
grade donor cells
6.1. Autologous vs. allogenic donor cells
Although hiPSC technology allows for the development of
autologous cell therapies, this approach may not be universally
Table 1
Quality control testing of reprogramming vectors.
Test Description
Identity Restriction digest with AGE, sequencing
Vector concentration DNA concentration by UV, viral vector titer
Vector quality HPLC assay for plasmid form, assay for viral
vector activity
pH/osmolality pH/osmolality measurement
Sterility/mycoplasma Testing for contamination by bacteria, fungi,
or mycoplasma as required by 21 CFR 610
Purity e endotoxin Limulus Amoebocyte Lysate (LAL) assay
Host impurities Assays for residual DNA, RNA, protein from
the vector production host
Viral pathogens In vitro, In vivo and species-speciﬁc pathogen
testing as recommended by ICH for the speciﬁc
vector production host and method
L.S. Wright et al. / Experimental Eye Research 123 (2014) 161e172 167optimal or necessary. Thus, it is important during the early stages of
designing hiPSC therapeutics to decide between pursuing autolo-
gous vs. allogeneic cell therapy. Autologous therapeutics address
the key issue of rejection of the cell transplant; however, this choice
also comes with a number of potential challenges from a
manufacturing and regulatory perspective. First of all, a
manufacturing process for an autologous therapeutic must be able
to handle patient-to-patient variabilities that could arise from a
number of factors, including donor age, gender and health. These
issues could impact the consistency, quality and safety of the ﬁnal
cell product. Extensive development and validation studies may be
required to demonstrate the ability of the cell manufacturing pro-
cess to handle such variabilities in the starting cell source. It is also
worth noting that an autologous therapeutic may pose an increased
risk of tumor formation and require long-term tumorigenicity
studies since the patient would not be expected to launch an im-
mune response against the graft.
The alternative choice to use allogeneic cells allows well-
characterized cell banks to be established for each therapeutic. Of
course, the issue of rejection remains present for allogeneic cell
therapeutics, although the relative immune privilege believed to be
afforded by the eye might offset this risk (Streilein et al., 2002).
However, if retinal immune privilege is disrupted in certain retinal
diseases, the availability of HLA diverse banks of hiPSCs may offer a
compromise (Taylor et al., 2011, 2012). Alternatively, disruption of
the BETA-2 -MICROGLOBULIN gene in hiPSCs could be used to
generate lines with reduced immunogenicity, analogous to a report
using hESCs (Riolobos et al., 2013). By employing one or more of
these approaches, the need for immunosuppression following
hiPSC transplantation may be minimized or eliminated, depending
on the degree of HLA matching required.
6.2. Early-stage cell manufacturing process and assay development
As noted above, one of the biggest challenges in harnessing the
potential of hiPSCs is the inherent variability in the cell production
process. This variability can be inﬂuenced by the quality of the
starting cell source, differences in the raw materials used for
reprogramming and cell culture, and protocols employed for hiPSC
growth and differentiation. Identifying and controlling these vari-
ables, and demonstrating that they do not introduce unacceptable
risk, is necessary to develop a cGMP manufacturing process. The
ﬁrst steps are to establish standardized, robust methods for
growing and differentiating cells, evaluating critical raw materials
(e.g., culture medium, growth factors), and performing quality
control (QC) testing, the latter of which should be done early and
often. Qualiﬁcation trials and QC assays are needed to demonstrate
process reproducibility and the ability to consistently produce a cell
therapeutic that meets key speciﬁcations (e.g., viability, purity,
function, sterility, and efﬁcacy).
6.3. Material for pre-clinical testing and human clinical trials
Once the process and assay development stage of a hiPSC
project is completed, material is typically produced for pre-clinical
animal studies to support federal applications for human clinical
trials. It is important to ensure that the ﬁnal cell product used in the
animal studies is representative of the therapeutic that will be
provided for the human clinical trial. If possible, identical cell
banks, raw materials and QC testing should be employed. The pre-
clinical animal studies must address key issues regarding the safety
of the transplanted cell product, which include the impact of off
target cell contaminants present in the donor cell population, the
potential for teratoma formation due to residual undifferentiated
cells, and the generation of karyotypically abnormal cells. As such,it is critical that any aspects of the process that could impact the
quality of the therapeutic are identical between cells produced for
animal studies and human clinical trials. In addition, a dialog
should be established with the appropriate federal agency (e.g.,
Food and Drug Administration) to ensure that any process changes
that are anticipated in moving from animal studies to clinical
production will not pose signiﬁcant regulatory problems.6.4. Human tissue source
Regardless of what tissue is used as the starting cell material,
donors for hiPSCs will have to meet stringent eligibility re-
quirements (e.g., HCT/P regulations 21 CFR 1271, Subpart C e Donor
Eligibility) (FDA, 2007). In addition, an informed consent document
should be executed at the time of collection to ensure that the
donor is aware of the intended use and required testing of his or her
samples, and that the tissue and data will be collected and treated
in an ethical manner (Lowenthal et al., 2012). For allogeneic hiPSCs,
donor eligibility requirements typically include testing of the pa-
tient for human pathogens such as HIV 1, HIV 2, Hepatitis B virus
(HBV), Hepatitis C virus (HCV), and Treponema pallidum. In addition,
for leukocyte-rich donor tissues, Human T-lymphotropic virus
(HTLV-I/II) and CMV testing is often necessary. While tissues that
are collected for generating autologous iPSCs are exempt from
donor eligibility requirements, testing may still be prudent given
the risk of facility cross-contamination and the potential to activate
latent pathogens during reprogramming and differentiation.6.5. Reprogramming method
Initial reprogramming methods relied on the use of retroviral
vectors (Takahashi et al., 2007; Yu et al., 2007). However, these
methods are not ideal for generating clinical-grade hiPSCs for
several reasons, including the potential for insertional mutagenesis
(Okano et al., 2013). To address this problem, major advancements
in reprogramming methodology have been made since the original
viral integrating vectors were described. Alternatives now include
nonviral methods (e.g., episomal and plasmid-based vectors, re-
combinant protein transduction, synthetic mRNA), or higher efﬁ-
ciency, nonintegrating adeno-, recombinant adeno-associated and
Sendai viruses or excisable lentivirus constructs [for reviews, see
Hussein and Nagy, 2012; Okita and Yamanaka, 2011]. Each of these
reprogramming methods has advantages and disadvantages with
respect to reprogramming efﬁciency, procedural logistics, somatic
cell source, requirement for feeder cells and cGMP compliance. For
example, the use of Sendai virus is limited by the fact that cGMP
compliant vectors are not currently available. Viral vectors that are
produced using untested cell linesmay introduce additional risks of
Table 2
Proposed testing for iPSC master cell banks.
Test Description
Identity Short tandem repeat testing
Viable cell count Trypan Blue dye exclusion
Bacterial/fungal
contamination
Bacteria and fungi testing (according
to 21 CFR 610.12)
Mycoplasma contamination Direct culture in broth and agar,
indirect test using indicator
culture/DNA stain (assay conditions
meet the FDA’s PTC requirements)
Karyotype G-band on 20 metaphase spreads
Cell marker expression Flow cytometry for human pluripotent stem cell
marker expression, including
Oct-3/4, SSEA-1/3/4, TRA-1-60, TRA-1-81
In vitro adventitious
agent testing
ICH cell line testing on 3 cell
lines (e.g., MRC5, Vero, NIH 3T3/Hs68)
Residual reprogramming
vector
PCR or Southern Blot to detect
and map residual reprogramming vector
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applications. However, EBV vectors can easily be produced in a
cGMP-compliant manner using expression in standard E. coli cell
lines with deﬁned, animal-free fermentation medium. The EBV
vector system has been used to reprogram a variety of cell types
including human ﬁbroblasts, mononuclear cells from bonemarrow,
and cord blood (Hu et al., 2011; Yu et al., 2009). More recently, a
method of reprogramming CD34þ cells fromwhole blood using EBV
episomal vectors was shown to support the generation of hiPSCs
from a wide range of donors (Mack et al., 2011).
While hiPSC reprogramming vectors used for clinical applica-
tions should ideally be produced under cGMP guidelines, the level
of cGMP compliance that is required depends in part on the system
used to create the vector, and whether the vector is present in the
ﬁnal hiPSCs. For example, viral vectors that are used in reprog-
ramming are typically produced in mammalian cell lines utilizing
culture medium that may contain animal-derived raw materials
such as fetal bovine serum. These viral vectors, and ideally the cell
line used to produce the viral vector, should be subjected to
adventitious agent testing to rule out introduction of pathogens
from the cell line and/or animal-derived raw materials (Table 1).
6.6. hiPSC bank production
For allogeneic cell therapeutics, a bank of starting cell material is
usually established in the early stages of product development. A
single Master Cell Bank (MCB) or a two-tiered system with a
Working Cell Bank is produced and tested to insure that the starting
material for the manufacturing process is consistent. For autolo-
gous therapeutics, generating a large hiPSC bank is not necessary.
However, creating a small bank of hiPSCs may help identify and
minimize variability that can arise from the initial reprogramming
step. The description of cell bank production and testing provided
below focuses on allogeneic applications; however, smaller banks
and scaled-back testing schemes may be more appropriate for
some applications.
To produce a MCB, several hiPSC colonies are selected and
screened to ensure that they meet speciﬁcations (e.g., bacterial/
fungal/mycoplasma contaminate, growth characteristics, karyo-
type, hiPSC marker expression) before choosing one to expand into
an MCB. The entire MCB manufacturing process should minimize
the use of animal-derived reagents wherever possible andmaintain
complete traceability of all materials. If animal components cannot
be replaced, they should be obtained from companies that tightly
control and rigorously test the source material.
Methods have been described for the expansion of pluripotent
stem cells using completely deﬁned, xeno-free cell culture medium
and attachment matrices (Chen et al., 2011; Kim et al., 2013; Rajala
et al., 2010; Wang et al., 2012). hiPSCs are expanded a pre-
determined amount based on the intended use of the bank, taking
into consideration the disease indication and expected future need.
Cells are usually stored in vapor phase liquid nitrogen using a
controlled freezing method and, preferably, a cryopreservation
medium formulation that is free of animal-derived components.
Cell Bank testing for adventitious agents is a critical part of devel-
oping cell lines for use in clinical production, which need to meet
requirements established by appropriate federal agencies (e.g., FDA
and the International Conference on Harmonization) (FDA, 1993;
ICH, 1998) (Table 2). In addition, special project-speciﬁc testing
(e.g., directed differentiation testing) should be considered.
6.7. hiPSC differentiation to the ﬁnal cell product
The differentiation stage of the manufacturing process will be
initiated from a cell bank or culture that has been subjected to theQC testing discussed above. From the research stage of develop-
ment to cGMP production, the differentiation process should be
developed to accomplish four main tasks: 1) minimize undeﬁned
or animal-derived raw materials, 2) ensure that the process is
robust enough to handle variability in the starting hiPSCs, 3)
conﬁrm that the process is scalable tomeet projected demands, and
4) reduce or eliminate the presence of unwanted cell types and
residual undifferentiated cells. Toward this end, chemically deﬁned
and non-xenogenic methods have been developed for retinal dif-
ferentiation from hiPSCs (Sridhar et al., 2013; Tucker et al., 2013).
Scalability of the manufacturing process is an important issue to
consider from the onset of product development. Research-based
methods that are very manual in nature are not ideal for produc-
ing larger batches of cells (scale-up) for allogeneic therapies, or for
use in high-throughput culture methods (scale-out) that may be
required to make an autologous therapeutic commercially feasible.
Moreover, scale-up or scale-out of the manufacturing process could
result in signiﬁcant changes in the quality of the ﬁnal product. The
differentiated cells are grown to a ﬁnal scale that provides adequate
cell numbers for dosing and sufﬁcient cells for QC testing and
archive samples. The ﬁnal cell product could take on many forms,
including fresh or cryopreserved dissociated cells, 3-D structures,
or cells seeded onto a scaffold. A cryopreserved ﬁnal cell product or
intermediate cell type is ideal as it allows QC testing to be per-
formed on the cell therapeutic prior to release to the clinic. Of note,
a method for efﬁcient cryopreservation of stratiﬁed 3-D retinal
cultures from hESCs has been described (Nakano et al., 2012) that
may be applicable to similar structures derived from hiPSCs.
However, cryopreserved cells will likely require some level of
manipulation (e.g., thaw and wash to remove DMSO) prior to
administration. Therefore, additional studies will need to be per-
formed to evaluate the effects of post-release handling of the cell
therapeutic, including shipping, storage, thawing/washing or post-
thaw culture.
QC testing should also be designed to accommodate the ﬁnal
cell format and preparation procedures. A summary of anticipated
QC testing for a hiPSC therapeutic is provided in Table 3, although
abbreviated QC testing may be permissible for products that are
prepared fresh for each administration, followed by more rigorous
testing. For example, when fresh cells are administered to patients,
there is not sufﬁcient time to perform the standard sterility test (14
days). In this case, federal regulatory agencies typically ask for a
rapidmethod (e.g., gram stain) to detect gross contaminationwith a
follow-up full sterility test. A plan must be in place to address po-
tential failing results in the sterility test if the product is adminis-
tered to a patient. Other critical assays, such as the determination of
Table 3
Quality control testing plan of the ﬁnal cell product.
Attribute Method Speciﬁcation
Pre and post-thaw viable cell recovery Trypan blue or other viability assessment >70%
Identity test Short Tandem Repeat Matches iPSC MCB
Bacterial endotoxin Kinetic chromogenic LAL <5 EU/mL
Mycoplasma PCR (validated) or PTC method (direct and indirect culture) No contamination
Sterility test Gram stain for fresh product, bacteristasis and fungistasis
(according to 21 CFR 610.12)
No contamination
Cell surface markers Flow cytometry assay for: positive markers speciﬁc for desired cell type, and
negative markers speciﬁc for off-target cells
Above (positive) or below (negative)
pre-determined limits of marker expressiona
Residual undifferentiated iPSCs Flow cytometry or qPCR assay for expression of Oct-3/4 or SSEA4 Below limits of detection
Potency Functional assessment of cell performance Establish by Phase 3 trials
a The appropriate positive and negative markers for each speciﬁc cell type should be based on the individual target cell(s), typical cell impurities, potential safety concerns,
and speciﬁcations developed through the manufacturing process for that particular cell product.
L.S. Wright et al. / Experimental Eye Research 123 (2014) 161e172 169residual undifferentiated cells, will be more challenging to address
in this situation and may need to be performed on an intermediate
sample so that results are available prior to release of the cell
therapeutic to the clinic. Once manufacturing and QC testing are
complete, all documentation and test results need to be reviewed to
insure that the cell therapeutic was produced in compliance with
cGMP guidelines and appropriate Standard Operating Procedures,
and that the ﬁnal cell therapeutic meets all QC testing
speciﬁcations.
7. Conclusions
Prevention remains the most desirable strategy to address hu-
man disease. However, other approaches must be explored when a
particular disease cannot be held in check or when conventional
therapies are ineffective. Toward this end, cell replacement may
provide a viable treatment option for some severe retinal degen-
erative disorders such as AMD and RP. Key issues for a cell-basedFig. 3. Flowchart depicting the potential role of hiPSCs in retinal transptherapeutic include 1) adequate production and expansion of
desired cells, 2) puriﬁcation of donor cell type(s) with elimination
of contaminating cells, 3) long term graft survival and immuno-
genic compatibility, and 4) ethical implications. With these con-
siderations in mind, human pluripotent stem cells offer many
promising treatment avenues. Fig. 3 summarizes the potential role
of hiPSCs in retinal repair in relation to current hESC trials, with an
emphasis on minimizing the cost and complexity of the process.
Unmatched hESCs are currently the most convenient and inex-
pensive option, but could be subject to immune rejection as well as
ethical objections. In contrast, cell types derived from patient-
speciﬁc hiPSCs can be used for autologous transplantation, with
less concern for immune rejection. However, customized cell
therapy is expensive and time-consuming, and hiPSCs may need to
undergo gene correction prior to transplantation, further increasing
the overall burden of the treatment approach. The use of HLA-
matched allogeneic hiPSCs, although not ideal, may provide a
middle ground for some cell therapies. If each of these strategieslantation therapies relative to current and future hESC-based trials.
L.S. Wright et al. / Experimental Eye Research 123 (2014) 161e172170fails to eliminate the specter of immune rejection, some level of
chronic immunosuppression therapy or host immune conditioning
may be necessary. Ultimately, the optimal strategies will only be
deﬁnitively revealed through human clinical trials. However, the
groundwork for hiPSC-based retinal therapies has already been
laid, offering guarded hope to individuals suffering from presently
untreatable blinding diseases.
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